Quantifying associations of genotype, proteinuria and eGFR with long-term kidney outcomes in Alport Syndrome using data from the UK National Registry of Rare Kidney Diseases (RaDaR).

Technical Summary: Quantifying Associations of Genotype, Proteinuria, and eGFR with Long-Term Kidney Outcomes in Alport Syndrome

Problem Statement
Alport Syndrome (AS), a monogenic disorder caused by pathogenic variants in COL4A3, COL4A4, or COL4A5 genes, is a leading cause of kidney failure (KF). While clinical outcomes vary widely based on genotype (e.g., X-linked vs. autosomal recessive vs. heterozygous variants), there is a lack of comprehensive, long-term prognostic data defining the trajectories of kidney function decline and proteinuria. Previous studies have been limited by small sample sizes, short follow-up periods, or reliance on arbitrary "baseline" measurements that fail to capture disease progression dynamics. Furthermore, the utility of proteinuria and eGFR slope as surrogate endpoints for clinical trials in AS remains uncertain, particularly regarding how these markers interact with genotype and disease stage.

Methodology
This retrospective cohort study utilized data from the UK National Registry of Rare Kidney Diseases (RaDaR). The study included 1,032 individuals with AS (median follow-up: 11.6 years), comprising both genetically confirmed cases (n=603) and clinically diagnosed cases (n=429).

• Cohort Stratification: Patients were categorized by genotype into "Alport Syndrome" groups (Male X-linked AS [XLAS] or Autosomal Recessive AS [ARAS]) and "Heterozygous" groups (Female XLAS, heterozygous COL4A3/4 variants, and Thin Basement Membrane Nephropathy [TBMN]).
• Genetic Analysis: In the genotyped cohort (n=478), variants were classified as "protein length-altering" (e.g., truncating) or "non-protein length-altering" (e.g., missense/glycine substitutions).
• Statistical Modeling:
  • Kidney Survival: Analyzed using Kaplan-Meier methods and log-rank testing to assess time to KF (defined as initiation of kidney replacement therapy, eGFR ≤15 mL/min/1.73m², or death).
  • Trajectory Modeling: Mixed-effects regression models were employed to analyze eGFR slopes and proteinuria trajectories across CKD stages and ages.
  • Threshold Analysis: Time to KF was estimated from specific eGFR thresholds (90, 60, 45 mL/min/1.73m²) and proteinuria thresholds (≥0.3, ≥1.0, ≥3.0 g/g), stratified by median proteinuria levels.

Key Results

1. Non-Linear eGFR Decline: Across all genotypes, the rate of eGFR decline accelerated significantly with advancing CKD stage (p<0.001). For example, in Male XLAS, the annualized eGFR slope increased from -1.4 mL/min/1.73m²/year in CKD stage 1 to -6.4 mL/min/1.73m²/year in stage 4.
2. Genotype vs. Proteinuria: While genotype influenced the age of onset and early disease trajectory (with ARAS and Male XLAS reaching KF earlier than heterozygous groups), proteinuria emerged as a dominant predictor of progression. Proteinuria increased as eGFR declined and occurred earlier in severe genotypes.
3. Convergence of Outcomes: A critical finding was that once patients reached comparable levels of proteinuria (specifically ≥1.0 g/g and ≥3.0 g/g), short-term kidney survival (over 5 years) did not differ significantly between Alport Syndrome genotypes and heterozygous genotypes (log-rank p=0.14 and p=0.17, respectively). Differences in long-term survival emerged only after extended follow-up, and even then, the magnitude was modest.
4. Proteinuria as a Prognostic Marker: Higher proteinuria was strongly associated with shorter time to KF at all eGFR thresholds. At an eGFR of 45 mL/min/1.73m², the median time to KF was 3.0 years for patients with above-median proteinuria versus 6.5 years for those with below-median proteinuria (p<0.0001). Almost all patients who reached KF had developed proteinuria ≥0.3 g/g.
5. Variant Specificity: Within the genotyped cohort, protein length-altering variants were associated with a younger median age at KF compared to non-protein length-altering variants (30.2 vs. 41.8 years). Stop-gain variants specifically correlated with the earliest onset of KF.

Significance and Claims
The authors posit that these findings have direct implications for clinical care and the design of future clinical trials:

• Risk Stratification: The study suggests that once established glomerular injury (indicated by significant proteinuria) is present, prognosis is more closely linked to current disease activity (proteinuria levels) than to the underlying genotype. This supports the use of proteinuria as a key marker for risk stratification, particularly for individuals with heterozygous genotypes who might otherwise be considered low-risk.
• Surrogate Endpoints: The strong, consistent association between proteinuria and kidney failure across genotypes and eGFR levels provides disease-specific evidence supporting the use of proteinuria reduction as a surrogate endpoint in AS clinical trials. The authors note that while this does not independently validate proteinuria as a surrogate, it strengthens the biological plausibility and rationale for its use in interventional studies.
• eGFR Slope Interpretation: The observed non-linearity of eGFR decline (acceleration in later stages) cautions against the uncritical use of eGFR slope as a trial endpoint without careful adjustment for baseline disease stage, as short-term changes may not be comparable across different stages of CKD.
• Inclusivity in Trials: The consistency of findings between genetically confirmed and clinically diagnosed cohorts suggests that patients without genetic confirmation (e.g., those diagnosed in earlier eras) should not be excluded from future therapeutic trials.

The paper concludes that proteinuria serves as a robust integrator of genotype and disease duration, offering a practical tool for interpreting disease progression and potentially accelerating the evaluation of new therapies for Alport Syndrome.